Which class improves LV ejection fraction and helps prevent arrhythmias and ventricular rate control?

Which class improves LV ejection fraction and helps prevent arrhythmias and ventricular rate control?

• A. Digoxin
• B. ACE inhibitors
• C. Anticoagulants
• D. Beta blockers

Answer: (D)

Beta blockers in heart failure with reduced ejection fraction work by blunting the heart’s overactive sympathetic drive. This slows the heart rate, lowers oxygen demand, and reduces harmful remodeling of the left ventricle. Over weeks to months, these effects can lead to an actual improvement in how well the ventricle pumps, raising the ejection fraction. They also help prevent arrhythmias and improve ventricular rate control. By dampening sympathetic stimulation, they stabilize electrical activity and reduce the likelihood of dangerous fast rhythms. In situations like atrial fibrillation, slowing the ventricular response helps the heart fill better and operate more efficiently. Other options don’t maximize these combined benefits. ACE inhibitors improve EF mainly through afterload reduction and remodeling but don’t provide the same direct rate-control and antiarrhythmic protection. Digoxin can aid symptoms and rate control in AF but doesn’t reliably improve EF long-term or mortality. Anticoagulants don’t affect the heart’s pumping ability or rhythm.

Beta blockers in heart failure with reduced ejection fraction work by blunting the heart’s overactive sympathetic drive. This slows the heart rate, lowers oxygen demand, and reduces harmful remodeling of the left ventricle. Over weeks to months, these effects can lead to an actual improvement in how well the ventricle pumps, raising the ejection fraction.

They also help prevent arrhythmias and improve ventricular rate control. By dampening sympathetic stimulation, they stabilize electrical activity and reduce the likelihood of dangerous fast rhythms. In situations like atrial fibrillation, slowing the ventricular response helps the heart fill better and operate more efficiently.

Other options don’t maximize these combined benefits. ACE inhibitors improve EF mainly through afterload reduction and remodeling but don’t provide the same direct rate-control and antiarrhythmic protection. Digoxin can aid symptoms and rate control in AF but doesn’t reliably improve EF long-term or mortality. Anticoagulants don’t affect the heart’s pumping ability or rhythm.